• DSM-Firmenich's Q3 2026 adjusted EBITDA rose 5% year-over-year to EUR 482 million; sales climbed 6% to EUR 2.37 billion.
• The cost savings and restructuring program remained on track, while management reported supportive fourth-quarter business conditions.
• For FY26, the group expects an adjusted EBITDA margin of around 20%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DSM-Firmenich AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040100OMX_____CNEWS_EN_GNW1001301610_en) on November 04, 2026, and is solely responsible for the information contained therein.